URO-1, Inc. is a life sciences company dedicated to advancing the tools and workflows used in soft tissue biopsy diagnostics.

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript March 6, 2026 Operator: Good day, and thank you for standing by. Welcome to the Profound Medical Fourth Quarter 2025 Financial ...

MINNEAPOLIS, March 5, 2026 /PRNewswire/ — Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) ...

Given that one in two people will develop cancer in their lifetime, it’s in everyone’s interest to be up to speed on the ...

My daughter, the second her eyes open, without a care for anyone sleeping or what time it might be, right when the rosy ...

DeepHealth is introducing in Europe its cloud-first integrated portfolio combining clinical AI, multi-modality viewing and reporting, which is designed to improve outcomes, efficiency and access to ca ...

When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

The disease entered Linda Adhiambo’s family in 2007 and never left. It has taken her mother, grandmother, aunt and cousins. Now, as she battles breast cancer, she asks: when will this cycle end?

Molecular profiling of tumors has been shown to improve risk stratification, and it may be useful for prostate cancer active surveillance.

Profound Medical (NASDAQ:PROF) reported fourth-quarter 2025 revenue of $6.0 million, including $2.3 million in recurring ...

Can AI match radiologists in prostate MRI diagnosis? The PARADIGM trial will assess AI detection of clinically significant ...